Trial settles debate over best design for mRNA in COVID vaccines.

Dolgin, Elie

Dolgin, Elie.

Nature ; 613(7944): 419-420, 2023 01.

Article in English | MEDLINE | ID: covidwho-2185711

Subject(s)

COVID-19 Vaccines; COVID-19; Clinical Trials as Topic; Drug Design; RNA, Messenger; Vaccine Development; mRNA Vaccines; Humans; COVID-19/prevention & control; COVID-19 Vaccines/chemistry; COVID-19 Vaccines/genetics; RNA, Messenger/chemistry; RNA, Messenger/genetics; mRNA Vaccines/chemistry; mRNA Vaccines/genetics; Vaccine Development/standards; Drug Design/standards

Keywords

Biochemistry; Biotechnology; SARS-CoV-2; Vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA, Messenger / Drug Design / Clinical Trials as Topic / COVID-19 Vaccines / COVID-19 / MRNA Vaccines / Vaccine Development Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Nature Year: 2023 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google